Aflibercept vs. Ranibizumab: cost ‐effectiveness of treatment for wet age‐related macular degeneration in Sweden

ConclusionResults suggest, in Sweden, at parity price level, IVT‐AFL is less costly than RBZ q4, while demonstrating similar efficacy; IVT‐AFL is cost‐effective versus RBZ PRN.

Source: Acta Ophthalmologica - April 6, 2016 Category: Opthalmology Authors: Hemangi R. Panchmatia, Karen M. Clements, Erin Hulbert, Marianne Eriksson, Kim Wittrup ‐Jensen, Jonas Nilsson, Milton C. Weinstein Tags: Original Article Source Type: research